Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
750 Views
eMediNexus 25 June 2021
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for the use of tocilizumab to treat hospitalized adults and children, aged 2 years and above, who are being given systemic corticosteroids and need supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
The drug is not authorized for use in outpatients. Clinical trials conducted among hospitalized COVID-19 patients revealed that the use of tocilizumab, along with routine care for treatment of COVID-19, including corticosteroid therapy, led to a reduction in the risk of death through 28 days of follow-up. It also reduced the duration of hospital stay.
Tocilizumab is a monoclonal antibody that works by decreasing inflammation as it blocks interleukin-6 receptor… (FDA, June 24, 2021)
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}